Recurrent Glioblastoma - Pipeline Insight, 2024

Recurrent Glioblastoma - Pipeline Insight, 2024

DelveInsight’s, “Recurrent Glioblastoma - Pipeline Insight, 2024,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Recurrent Glioblastoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Recurrent Glioblastoma Understanding

Recurrent Glioblastoma: Overview

Recurrent glioblastoma is a possibility that oncologists – and patients – must keep in mind during and after an initial course of treatment. Because it can be difficult to completely remove a tumor during surgery, there is always a possibility that the cancer might come back after a period of remission. As a result, survivors are typically scheduled for follow-up appointments and surveillance imaging every few months after the completion of their initial treatments. Glioblastoma can come back anywhere in the brain or spinal cord. However, most recurrences are found near the site of the original tumor. Without treatment, the median survival with glioblastoma is only a few months, but even with treatment, survival is frequently only around one year. The five-year survival rate from the disease is roughly 5.0%. For people who have surgery to remove as much of the tumor as possible along with radiation and chemotherapy, the overall median survival (the time after which 50% of people have died and 50% are still alive) is only 14 months. There are treatment options for recurrent glioblastoma, though as noted by looking at survival statistics, few of these have led to long-term survival with the disease. Some treatments do improve survival, and several can improve quality of life. That said, many of these newer treatments have only recently been evaluated in humans, and it's too soon to know what the potential long-term benefit may be.

""Recurrent Glioblastoma - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Recurrent Glioblastoma pipeline landscape is provided which includes the disease overview and Recurrent Glioblastoma treatment guidelines. The assessment part of the report embraces, in depth Recurrent Glioblastoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Recurrent Glioblastoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Recurrent Glioblastoma.
• In the coming years, the Recurrent Glioblastoma market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics that are working to assess challenges and seek opportunities that could influence Recurrent Glioblastoma R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• A detailed portfolio of major pharma players who are involved in fueling the Recurrent Glioblastoma treatment market. Several potential therapies for Recurrent Glioblastoma are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Recurrent Glioblastoma market size in the coming years.
• Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Recurrent Glioblastoma) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Recurrent Glioblastoma Emerging Drugs Chapters

This segment of the Recurrent Glioblastoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Recurrent Glioblastoma Emerging Drugs

• ASC40: Ascletis

ASC40 is an oral, selective inhibitor of fatty acid synthase (FASN), a key enzyme which regulates de novo lipogenesis (DNL). ASC40 inhibits energy supply and disturbs membrane phospholipid composition of tumor cells by blocking de novo lipogenesis. In January 2022, Ascletis Pharma Inc. announced the dosing of the first patient in the Phase III registration clinical trial of ASC40 combined with bevacizumab for treatment of recurrent glioblastoma (rGBM). The Phase II study, completed in the U.S., in patients with rGBM has shown that the objective response rate (ORR) for ASC40 plus Bevacizumab treatment was 65% including a complete response (CR) of 20% and a partial response (PR) of 45%.

• GX-I7: Genexine

GX-I7 is a long-acting human IL-7 which is essential for homeostatic T cell proliferation and improves lymphopenia, typically induced by chemotherapy or radiation therapy. The safety has been proved via phase I clinical trial in healthy volunteers and phase Ib and Ib/2 Clinical trials are being conducted to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics and efficacy.

• Olinvacimab: PharmAbcine

Olinvacimab is an anti-angiogenic antibody that neutralizes the VEGF/VEGFR2 pathway, thus inhibiting tumor growth and metastasis. It blocks the binding of all VEGFR ligands such as VEGF-A, VEGF-C and VEGF-D to VEGFR2. To gain nutrients and oxygen needed for growth, tumor cells release these VEGF ligands which promote angiogenesis (a formation of new blood vessels) that will enhance tumor blood supply. Binding of olinvacimab to VEGFR2 will result in the inhibition of VEGF-mediated tumor angiogenesis.

• VXM01: VAXIMM AG

VXM01 is an oral T-cell immunotherapy that is designed to activate T-cells to attack the tumor vasculature and, in several tumor types, attack cancer cells directly. VXM01 carries the vascular endothelial growth factor receptor-2 (VEGFR2), which is highly overexpressed on the tumor vasculature and on certain cancer cells as the target gene. The active, T-cell-mediated destruction of tumor vasculature cells leads to an increased infiltration of various immune cells into tumor tissue (inflammation). In preclinical studies, a murine analog VXM01 vaccine showed broad anti-tumor activity in different tumor types. This activity was linked to a VEGFR2-specific T-cell response and was accompanied by the destruction of the tumor vasculature and increased immune cell infiltration. A Phase I/II trial evaluating VXM01 in combination with avelumab, a human anti-PD-L1 antibody, for the treatment of glioblastoma is ongoing. The trial is part of a collaboration agreement with Merck KGaA, Darmstadt, Germany and Pfizer Inc. VXM01 has received orphan designation from the European Commission and from the US Food and Drug Administration (FDA) for the treatment of glioblastoma.

Further product details are provided in the report……..

Recurrent Glioblastoma: Therapeutic Assessment

This segment of the report provides insights about the different Recurrent Glioblastoma drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Recurrent Glioblastoma

There are approx. 50+ key companies which are developing the therapies for Recurrent Glioblastoma. The companies which have their Recurrent Glioblastoma drug candidates in the most advanced stage, i.e. phase III include, Ascletis.

• Phases

DelveInsight’s report covers around 50+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Recurrent Glioblastoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous
• Molecule Type

Products have been categorized under various Molecule types such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Recurrent Glioblastoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Recurrent Glioblastoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Recurrent Glioblastoma drugs.

Recurrent Glioblastoma Report Insights

• Recurrent Glioblastoma Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Recurrent Glioblastoma Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Recurrent Glioblastoma drugs?
• How many Recurrent Glioblastoma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Recurrent Glioblastoma?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Recurrent Glioblastoma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Recurrent Glioblastoma and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Ascletis
• Genexine
• PharmAbcine
• VAXIMM AG
• WPD Pharmaceuticals
• Accendatech USA Inc.
• Midatech Ltd
• MediciNova
• Kadmon Corporation, LLC
• Istari Oncology, Inc.
• Bristol-Myers Squibb
• Novartis
• Jiangsu Hengrui Medicine
• Peloton Therapeutics, Inc.
• Karyopharm Therapeutics
• VBL Therapeutics
• Nerviano Medical Sciences
• Acerta Pharma BV
• Basilea Pharmaceutica
• DNAtrix, Inc.
• NanoPharmaceuticals LLC
• Erasca, Inc.
• Oblato, Inc.
• OX2 Therapeutics
• Crimson Biopharm Inc.
• Merck Sharp & Dohme LLC
• Transgene
• CANbridge Life Sciences Ltd.
• Eli Lilly and Company
• Arcus Biosciences, Inc.
• Incyte Corporation
• BerGenBio ASA
• Istari Oncology, Inc.
• Chimerix

Key Products

• ASC40
• GX-I7
• Olinvacimab
• VB-111
• VXM01
• NMS-03305293
• ONC201
• PVSRIPO
• AB122
• TG6002
• OKN-007
• BGB 324
• CAN008
• Pembrolizumab
• Abemaciclib
• hP1A8
• INCMGA00012
• CM93
• ERAS-801
• fb-PMT
• BAL101553
• DNX-2440
• ACP-196
• Berubicin Hydrochloride
• ACT001
• MTX110
• MN-166
• Tesevatinib
• Lerapolturev
• Nivolumab
• BGJ398
• Camrelizumab
• PT2385
• Selinexor

Show more